Synapse Open Synapse
Biology

Kodiak skyrockets on positive study data for 2 eye drugs

BioPharma Dive · · 2 min read

The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.

Latest from BioPharma Dive